The Korea Technology Finance Corporation (Korea Technology Finance Corporation, Chairman Kim Jong-ho, hereinafter referred to as KIBO) announced on the 16th that it selected C&Cure Co., Ltd. (Co-CEOs Min Jeong-jun and Park Jung-gon) as an 'IP-Value Powerhouse' and provided KRW 1 billion in excellent IP value plus guarantee (hereinafter referred to as 'Value Plus Guarantee') reflecting the results of the value assessment of technology related to bacteria-based immune anticancer drugs.
The Value Plus Guarantee is a customized guarantee product that discovers excellent IPs in high value-added cutting-edge technology fields among the intellectual property (IP) owned by small and medium-sized enterprises and supports commercialization funds by linking them with guarantees within the calculated value amount. Kibo is awarding the 'IP-Value Powerhouse Small and Medium-sized Enterprise' certificate to excellent IP companies selected through high-difficulty technology value evaluation, and the award ceremony was held at Kibo Honam Regional Headquarters on this day with the attendance of the CEO of C&Cure Co., Ltd.
C&Cure Co., Ltd. is a biotech company located in Gwangju Metropolitan City, established in August 2019 by CEO Min Jeong-jun (President of Hwasun Chonnam National University Hospital), developing bacteria-based immunotherapy and diagnostic radiopharmaceuticals. In particular, the bacteria-based anticancer treatment is a new concept cancer immunotherapy using non-toxic Salmonella, and has both the cancer cell killing efficacy of existing chemotherapy drugs and the cancer cell targeting specificity of targeted anticancer drugs. In addition, this technology has the advantage of suppressing the immune evasion of cancer cells and activating the immune system, and is evaluated as an innovative anticancer treatment technology.
Kibo highly evaluated the technological prowess and business growth potential of C&Cure Co., Ltd. and provided a value plus guarantee of KRW 1 billion. It also plans to actively support the commercialization of excellent IPs by providing various benefits such as ▲guarantee fee reduction ▲free support for pre-diagnosis evaluation for technology special listing ▲technology evaluation certification for investment purposes.
Lee Jae-pil, CEO of Kibo, said, “In the case of the bio industry, it takes a long time for the results of new drug development to become visible, and continuous funding is needed according to the development stage.” He added, “Going forward, Kibo will actively discover bio venture companies with excellent IP and do its best to foster the bio industry by linking customized policies such as full-cycle R&D support and research infrastructure establishment to secure original technologies.”
- See more related articles
You must be logged in to post a comment.